- Home
- ATO vs ROIV Comparison
ATO vs ROIV Comparison
Compare ATO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATO | ROIV |
|---|---|---|
| Founded | 1906 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8B | 23.2B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ATO | ROIV |
|---|---|---|
| Price | $174.71 | $34.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $182.25 | $28.94 |
| AVG Volume (30 Days) | 1.4M | ★ 5.5M |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ 9.22 | N/A |
| EPS | ★ 5.92 | N/A |
| Revenue | ★ $4,702,755,000.00 | $8,260,000.00 |
| Revenue This Year | $15.32 | N/A |
| Revenue Next Year | $10.09 | $744.61 |
| P/E Ratio | $29.33 | ★ N/A |
| Revenue Growth | ★ 12.91 | N/A |
| 52 Week Low | $149.98 | $10.71 |
| 52 Week High | $192.51 | $34.68 |
Technical Indicators
Market Signals| Indicator | ATO | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 70.33 |
| Support Level | $165.13 | $26.65 |
| Resistance Level | $180.17 | N/A |
| Average True Range (ATR) | 2.39 | 1.13 |
| MACD | 1.05 | 0.45 |
| Stochastic Oscillator | 81.05 | 85.77 |
Price Performance
Historical ComparisonAbout ATO Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3.3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.